Lexicon Genetics Lands Merck as Licensee

Aug 23, 2001

NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.

Details of the agreement were not disclosed.

Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in PLOS

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Even More Data to Mine

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

New Spaces in Connecticut

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Healthier, If Not Longer, Life

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.

Main menu